Trial Profile
A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD [DYNAGITO]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms DYNAGITO
- Sponsors Boehringer Ingelheim; Unilfarma
- 19 May 2021 Results of pooled analysis from six studies (TONADO 1-2, DYNAGITO, WISDOM, UPLIFT and TIOSPIR) comparing the time to all-cause mortality with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderate-to-severe COPD and a predominantly lower exacerbation risk, presented at the 117th International Conference of the American Thoracic Society.
- 19 Nov 2020 Data from (TONADO and DYNAGITO trials) were used to assess cost effectiveness of Tiotropium+Olodaterol Versus Tiotropium and Laba/Ics presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 10 Aug 2020 Results (n=9942) of post-hoc pooled analysis of three studies (TONADO-1, TONADO-2 & DYNAGITO) assessing effect of tiotropium/olodaterol in reducing rate of severe exacerbations in COPD patients, published in the Advances in Therapy.